Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 52-Week High – What’s Next?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $34.84 and last traded at $33.8450, with a volume of 84505 shares trading hands. The stock had previously closed at $33.00.

Wall Street Analyst Weigh In

CHGCY has been the topic of several recent research reports. UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Smbc Nikko Sec. upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, Chugai Pharmaceutical currently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

The firm has a market capitalization of $110.40 billion, a P/E ratio of 38.56 and a beta of 0.63. The stock’s 50 day simple moving average is $28.15 and its 200 day simple moving average is $25.32.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The firm had revenue of $2.25 billion during the quarter. On average, analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.